A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Mometasone Furoate/Azelastine Hydrochloride Combination Group and Mometasone Furoate and Azelastine Hydrochloride Group 4 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Perennial Allergic Rhinitis Patient.

NCT01470053 Phase 3 COMPLETED

The purpose of this study is to evaluate of efficacy and safety of mometasone furoate plus azelastine HCl in patients with perennial allergic rhinitis.

Details

Lead sponsor	Hanlim Pharm. Co., Ltd.
Phase	Phase 3
Status	COMPLETED
Enrolment	347
Start date	2011-03
Completion	2012-11

Conditions

• Perennial Allergic Rhinitis

Interventions

• mometasone furoate plus azelastine HCl
• mometasone furoate
• azelastine HCl

Primary outcomes

• change from baseline in rTNSS(reflective Total Nasal Symptom Score) — 4 weeks

Countries

South Korea